IngredientsElecampane, scientifically known as Inula helenium, is a herb with a rich history in traditional herbal medicine, tracing back to ancient Greek and Roman cultures. Synonyms include Helenium grandiflorum Gilib., Aster officinalis All., and Aster helenium (L.) Scop. It belongs to the family Asteraceae (which also includes yarrow, dandelion, and daisy), with the root being the primary medicinal part used.
Inula, the Latin classical name for the plant, is considered to be a corruption of the Greek word Helenion, which in its Latinized form, Helenium, is also now applied to the same species. There are a few theories as to how elecampane came by its Latin name Inula helenium, some of which concern Helen of Troy: one holds that the plant grew where her tears fell, another that Helen had her arms full of elecampane when Paris stole her away, and yet another suggests that she first used it to cure snake bites. Common names such as "Elfwort" and "Horseheal" reflect its historical use in folklore and veterinary medicine. The common name "elfwort" is connected to the belief in Celtic times that the herb possessed magical properties, with elves variously believed to favour the plant and also to reside within it.
Elecampane is indigenous to southern and eastern Europe, but is also found in central Europe, the Near East, and North America. This perennial grows up to 3 meters in height, has large irregularly toothed leaves, and its golden yellow daisy-like flowers grow up to 7 centimeters in diameter. A native plant to southeastern Europe, elecampane was brought to North America by the European colonists.
The dried roots and rhizomes are collected in fall or early winter and used in herbal preparations. Inula helenium is one of the largest dicotyledonous herbaceous plants and is the richest source of inulin-type fructans, containing from 19–44% of the inulin-type fructans, with higher contents most typical in autumn.
Elecampane root supplements are available in dried and powdered form, liquid droppers, and teas. The root is traditionally administered as a decoction, prepared by boiling the comminuted herbal material and water, which is then strained before administration. Dosage recommendations in the British Herbal Pharmacopoeia (BHP) range from 1.5–4 g decoction from the dried root/rhizome, or 1.5–4 mL liquid extract (i.e., 1:1 herbal tincture in 25% alcohol) thrice daily. The British Herbal Pharmacopoeia recommends 1–2 g three times a day of dried roots and rhizomes. A low dose could be useful in long-term usage, for example 2 mL daily of tincture of the fresh root.
Secondary sources suggest 50–200 milligrams of alantolactone daily for two courses of five days with an interval of 10 days when used for antiparasitic purposes, or 7–12 drops of tinctured elecampane root daily for general use.
Elecampane root is also one of the ingredients historically used in the preparation of absinthe.
Elecampane was a food and a medicine in ancient times. It was a panacea plant for the ancient Greeks and Romans, used for everything from dropsy and uterine disorders to digestive and respiratory complaints. Ancient Romans valued elecampane as a digestive aid, while Pliny the Elder recommended daily consumption to promote digestion and well-being. Elecampane was known to the ancient writers on agriculture and natural history, and even the Roman poets were acquainted with it, and mention Inula as affording a root used both as a medicine and a condiment. Horace, in the Eighth Satire, relates how the Romans, after dining too richly, pined for turnips and the appetizing Enulas acidas.
By the 19th century, the Eclectics had adopted the plant into their materia medica, and it was included in the US Pharmacopeia of 1890. King's Dispensatory describes elecampane as "an aromatic stimulant and tonic, and is much used in chronic pulmonary affections and weakness of the digestive organs." It has a long history of use for "old coughs," especially in tuberculosis and for advanced lung conditions to help remove phlegm, such as bronchiectasis, pneumoconiosis, whooping cough, and bronchitis.
The common name "scabwort" came about from use of the root, boiled well in vinegar, beaten and made into a salve with suet or oil of trotters, for scabs or itch, including for use on sheep. Respiratory preparations in Irish traditions specified boiling the powdered herb with dilute barley water, liquorice, cinnamon and sugar, whilst digestive ailments were treated with a plaster applied to the navel, comprised of the herb boiled in wine and oil.
Westerners have traditionally used elecampane both as a medicine and a condiment or cordial for digestion, loss of appetite, and non-ulcer dyspepsia. It is considered not only expectorant but also carminative, diuretic, stomachic, antimicrobial, anthelmintic, anti-asthmatic, vulnerary, a gentle stimulant, and in large doses, emetic.
Indigenous tribes in North America, including the Cherokee and Iroquois, employed elecampane for respiratory and digestive health, as well as for pain relief and wound care. Native Americans used elecampane decoction to treat lung disorders and tuberculosis.
Isoalantolactone is one of the active components from many Traditional Chinese Medicine (TCM) materials and formulas including TuMuXiang (Radix inulae, dried roots of I. helenium and Inula racemosa), Mongolian medicine prescriptions Roukou Wuwei pills, Liuwei Anxiao San, Tibetan medicine Zuozhu Daxi, and Ershi-wei Chenxiang pills. In Chinese medicine, elecampane is a premier herb for descending rebellious Qi and transforming cold-phlegm, with the flowers (Xuan Fu Hua) historically included in many classic cough and nausea formulas such as Xuan Fu Dai Zhe Tang.
The Ayurvedic tradition uses elecampane for respiratory complaints and rheumatism as well as skin problems including bites and stings. It promotes the secretions and movement of the gut and is especially useful in cases where there is a weak digestion with "low digestive fire" — low Agni in Ayurvedic terms — where there may be poor appetite, bloating, wind, or foggy-headedness.
Elecampane root and rhizome contain approximately 1–4% volatile oils, and most of these volatile oils are composed of sesquiterpene lactones, including alantolactone. Its crystalline element, known as helenin, is a blend of three selinan-type sesquiterpene lactones: alantolactone, isoalantolactone, and dihydroalantolactone. Besides helenin, the essential oil contains minor amounts of alantol and proazulene.
Isoalantolactone (ISA) is a sesquiterpene lactone that can be isolated from Inula helenium as well as many other herbal plants belonging to Asteraceae. Over the past two decades, research has demonstrated multiple pharmacological effects including antimicrobial, anticancer, anti-inflammatory, neuroprotective, and antidepressant-like activity. The natural products attributing to the antimicrobial activity observed in vitro were identified as alantolactone (1), isoalantolactone (2), igalan (3), and an unseparated mixture of dugesialactone (4) and alloalantolactone (5), as major compounds.
Isoalantolactone and alantolactone together are used as the chemical markers of I. helenium.
Elecampane is very high in inulin (up to 44%) and mucilage. Inulin is not digested by human enzymes but is fermented by beneficial colonic bacteria, producing short-chain fatty acids (particularly butyrate) that nourish colonocytes and support gut barrier integrity. This prebiotic action underpins the traditional use of elecampane for digestive support. The inulin fraction is water-soluble and extracted in decoctions and infusions.
Elecampane root constituents include polysaccharides (up to 44% inulin), sesquiterpene lactones (alantolactone, isoalantolactone), sterols, resin, mucilage, and volatile oils. The aerial parts of the plant have up to 3% essential oil, while the leaves contain a bitter compound called alantopicrin. Polyphenols and flavones from elecampane have been shown to possess antioxidant, antitumor, and immunomodulatory properties.
Through inhibiting NF-κB signaling, isoalantolactone exerts its anti-inflammatory effects, which are also involved in the neuroprotective actions of this compound. Alantolactone can exhibit anti-inflammatory and anti-tumor activities through modulating abnormal signaling pathways in cancer cells. For example, mitogen-activated protein kinases (p38 MAPK) and NF-κB signaling pathways are significantly attenuated by alantolactone, inhibiting cell viability and promoting cell apoptosis in lung cancer cell lines.
Structure-activity relationship studies show that the α-methylene-γ-butyrolactone motif is essential for NO production suppression and that retaining the C1-OH group can markedly improve this effect. The NF-κB signaling pathway plays a pivotal role in the regulation of NO expression, and active compounds inhibit phosphorylation of p65 and p50 in TNF-α-induced NF-κB signaling.
The essential oil has antiseptic, anthelmintic, and anti-inflammatory properties, with the anthelmintic effects linked to alantolactones, which act similarly to santonin. Among the most potent bioactive compounds identified in antimycobacterial research, alantolactone was noted for its ability to affect the permeability of microbial plasma membranes, thus killing the mycobacterium species.
Based on the literature, alantolactone and isoalantolactone induce apoptosis by targeting multiple cellular signaling pathways that are frequently deregulated in cancers, suggesting that their simultaneous targeting by these compounds could result in efficacious and selective killing of cancer cells. Research on isoalantolactone indicates anticancer effects involving proliferation inhibition, ROS overproduction, apoptosis induction, and cell cycle arrest.
Alantolactone (ALT) effectively suppresses both constitutive and inducible STAT3 activation, inhibits its translocation into the nucleus, and decreases its DNA binding activity. Further mechanistic study revealed that ALT abrogates STAT3 activation by promoting STAT3 glutathionylation.
Most herbal texts attribute the actions of elecampane to alantolactone, but the antitussive (cough prevention and treatment) and carminative (soothing effect on the intestinal tract) effects of elecampane may possibly be due to the inulin and mucilage content.
Elecampane is considered a tonic for the lungs. It is a bronchospasmolytic, expectorant, and antimicrobial, making it a remedy of choice for lung disease including where infection is present. The British Herbal Pharmacopoeia lists the therapeutic actions of the herb as: antitussive, antiseptic expectorant, diaphoretic, and bactericidal. Suggested indications include respiratory mucosal catarrh (tracheal, bronchial), cough and phthisis associated with pulmonary tuberculosis, bronchitis, and whooping cough in infants.
Evidence strength: Some modern herbalists regard elecampane as a long-term treatment for respiratory diseases, such as asthma and bronchitis, especially when excessive mucus is a notable feature. However, there is no robust clinical evidence that it is effective for this purpose. Scientists need to do more human research to determine its safety, effectiveness, and standard dosing. Evidence at this time is largely based on traditional use, pharmacological plausibility from constituent studies, and in vitro or animal data, with no rigorous randomized controlled trials in humans identified.
In vitro anti-Staphylococcus aureus efficacy against both antibiotic-resistant and susceptible clinical isolates was documented for a hydroethanolic extract obtained from the rhizome and roots at concentrations between 0.9 and 9.0 mg/mL. Similar in vitro anti-staphylococcal activity was reported for (hydro)ethanolic root extracts of I. helenium naturalized in Ireland, supporting their traditional usage. A preliminary screen confirmed that crude extracts were active against gram-positive bacteria including Group-A Streptococcus pyogenes, Group-B Streptococcus agalactiae, Listeria monocytogenes, Escherichia faecalis ATCC 29212, and Escherichia coli, as well as Mycobacterium tuberculosis H37Ra (ATCC 25177).
Findings suggest that the geographical origin of the plant does not influence the anti-bacterial potency nor the chemical composition of traditional elecampane root.
Evidence strength: All antimicrobial data are in vitro (cell culture). No human clinical trials testing elecampane for bacterial infection have been identified in the peer-reviewed literature. The in vitro findings are scientifically notable, particularly regarding MRSA, but cannot be directly extrapolated to clinical efficacy.
In a bioassay-guided search for antimycobacterial compounds from higher plants, the root extracts of elecampane were chemically investigated for their active constituents. Chromatographic fractions of root extracts of I. helenium which exhibited significant activity against Mycobacterium tuberculosis provided the known eudesmanolides alantolactone, isoalantolactone, and 11αH,13-dihydroisoalantolactone. Alantolactone, isoalantolactone and its 4α,15-epoxide, 1,2-dehydro-3-epi-isotelekin, and alloalantolactone gave MICs of 32 micrograms/mL against M. tuberculosis.
Among medicinal plants studied in a review of MENA-region antimycobacterial plants, the extract of Inula helenium was noted as presenting some of the strongest anti-MTB activity.
Evidence strength: Entirely preclinical — in vitro radiorespirometric bioassay and cell culture studies. The traditional use for tuberculosis-related respiratory ailments is historically well-attested across multiple cultures, but no clinical trials of elecampane in tuberculosis patients have been identified.
Alantolactone (ALT) is a natural compound extracted from Inula helenium with therapeutic potential in the treatment of various diseases. In vitro and in vivo studies have indicated cytotoxic effects of ALT on various cancers, including liver cancer, colorectal cancer, and breast cancer. The inhibitory effects of ALT depend on several cancer-associated signaling pathways and abnormal regulatory factors in cancer cells.
To develop phytomedicine including sesquiterpene lactones, researchers prepared a hexane fraction from I. helenium (HFIH) and examined its inhibitory effect on STAT3 activation in human breast cancer MDA-MB-231 cells. HFIH selectively suppressed STAT3 phosphorylation at tyrosine 705, not affecting its upstream kinases, downregulated the expression of STAT3 target genes including cyclin D1, c-myc, and bcl-2, and induced caspase-mediated apoptosis.
In another in vitro study, the anticancer effects of alantolactone on the human breast cancer cell line MCF-7 were investigated. The cell viability reduced significantly compared with that of control cells. Alantolactone induced apoptosis of MCF-7 cells by regulating protein expression levels of Bcl-2, Bcl-2-associated X protein, p53, caspase-3, and caspase-12, and suppressed colony formation and migration by regulating the protein expression of MMP-2, MMP-7, and MMP-9.
In studies on A549 lung adenocarcinoma cells, alantolactone was found to effectively inhibit proliferation and trigger oxidative stress-mediated apoptosis by inducing ER stress and mitochondrial dysfunction. This ALT-mediated apoptosis was inhibited by NAC while diamide potentiated it.
The cytotoxicity of helenin (40% alantolactone and 60% isoalantolactone) isolated from I. helenium was evaluated along with four pharmaceutical antineoplastic drugs. Helenin suppressed cell growth at concentrations of 1–2 mg/mL, and notably, extracts of I. helenium roots displayed highly selective toxicity toward four different tumor cell lines but much lower toxicity against healthy human peripheral blood lymphocytes.
Many studies have shown that alantolactone and isoalantolactone induce apoptosis of many types of cancer cells; however, reports on the underlying mechanisms of action of these compounds are still limited. Emerging studies have reported several promising strategies to enhance the oral bioavailability of ALT, such as combining ALT with other herbs and using ALT-entrapped nanostructured carriers.
Evidence strength: All anticancer evidence is preclinical (in vitro cell culture and some animal models). There are no published human clinical trials of elecampane or its isolated constituents for cancer treatment. The in vitro findings across multiple cancer cell lines are consistent and mechanistically well-characterized, but translation to clinical utility remains entirely unproven.
Elecampane promotes the secretions and movement of the gut and is especially useful in cases where there is a weak digestion, poor appetite, bloating, or wind. Inulin is not digested by human enzymes but is fermented by beneficial colonic bacteria, producing short-chain fatty acids (particularly butyrate) that nourish colonocytes and support gut barrier integrity. This prebiotic action underpins the traditional use of elecampane for digestive support.
Evidence strength: The prebiotic mechanism of inulin is well-established in the general scientific literature through studies on dietary fiber, and elecampane's exceptionally high inulin content (up to 44% of dry root weight) provides strong biological plausibility for digestive support. However, no clinical trials specifically using elecampane root preparations for human digestive disorders have been identified.
Isolated alantolactone has been used to treat parasites (e.g., roundworm, threadworm, hookworm, whipworm). Alantolactone has been used in concentrated form as a treatment for intestinal parasites, but it is not clear whether the whole herb is particularly effective for this purpose.
Evidence strength: Historical and limited pharmacological. The anthelmintic use of isolated alantolactone is documented in older European medical traditions, but no modern controlled clinical trials evaluating whole-root elecampane for parasitic infections have been identified.
In an atopic dermatitis-like skin lesion mouse model, topical application of 1% elecampane root extract cream significantly reduced clinical symptoms via suppression of inflammatory cytokines in a dose-dependent manner.
Evidence strength: One animal model study. No human clinical trials for topical dermatological use have been identified.
In the 1980s, the German Commission E published an official monograph disproving the therapeutic use of elecampane root, based on insufficient evidence to support the efficacy of the herb and preparations thereof, and the risk of associated adverse effects. It was later considered an "unapproved" medicinal herb, and consequently excluded in consecutive global monographs and compendial texts from thereon, including the ESCOP monographs, WHO Selected Medicinal Herb monographs (Vols. 1–3), the British Herbal Compendium (Vols. 1 and 2), and the European Medicines Agency (EMA) official herbal monographs and list entries.
The German Commission E Monograph states that the historical application of elecampane has not been adequately proven to recommend its use, which is partially based on potential side effects. Despite its exclusion from major regulatory monographs, the pharmacological applications of plants in medicine can be guided by the attestation of traditional use, as demonstrated in recent antimicrobial research. Elecampane is not widely recommended for self-prescribing because of the risk of allergic contact dermatitis, though for practitioner usage it is regarded as an effective and important herb.
The German Commission E monograph had originally listed the root for loss of appetite, dyspepsia, and bronchial catarrh as historical applications, before the updated negative assessment.
The following dosages are reported in cited pharmacopoeial and clinical reference sources only:
At this time there is not enough scientific information to determine an appropriate range of doses for elecampane based on rigorous clinical data.
Large doses may cause gastrointestinal discomfort, vomiting, diarrhea, cramps, and symptoms of paralysis. Alantolactone can be an irritant to the intestinal tract and, along with other sesquiterpene lactones in elecampane, may cause localized irritation in the mouth. The high inulin content means that some individuals with FODMAP sensitivity may experience gas and bloating from elecampane preparations.
Elecampane may cause hypersensitivity reactions in patients with an existing allergy to plants in the Asteraceae family. Alantolactones may irritate the mucous membranes. There are case reports of contact dermatitis. The sesquiterpene lactones are responsible for the contact dermatitis risk associated with the plant, as they are moderate skin sensitizers. Individuals with a known allergy or hypersensitivity to elecampane or members of the Compositae/Asteraceae family — such as dandelion, goldenrod, ragweed, sunflower, and daisies — should avoid use.
Elecampane is considered likely unsafe to take when pregnant or breastfeeding. Information regarding safety and efficacy in pregnancy and lactation is lacking. Animal studies have suggested uterotonic activity.
There is some concern that elecampane may interfere with blood sugar control. Sesquiterpenes and fractions from Radix Inulae have also shown cardiovascular, hypoglycaemic, and insulin-sensitization activities in preclinical studies. Individuals using hypoglycemic agents should be aware of this potential interaction, though clinical evidence is lacking.
Elecampane affects the central nervous system and can cause sleepiness. There is a concern that it might cause too much sleepiness if combined with anesthesia and other medications used during and after surgery. Stopping use of elecampane at least 2 weeks before a scheduled surgery has been advised. Elecampane might cause sleepiness and slowed breathing, and this may compound the effects of sedative medications.
People with a confirmed sensitivity to inulin should avoid elecampane.
Health conditions that Elecampane may help support.
Elecampane root extracts and their constituent sesquiterpene lactones (especially isoalantolactone) have demonstrated antioxidant activity through Nrf2-mediated induction of detoxifying enzymes (NQO1, GST) and radical scavenging of phenolic compounds including chlorogenic and caffeic acids. Multiple in vitro studies confirm this activity.
Elecampane root contains up to 44% inulin, a prebiotic fructan with documented hypoglycemic properties in clinical studies. In vitro and animal data also suggest hypoglycemic activity from other constituents. Clinical evidence for inulin as a glucose-modulating prebiotic is well-supported, though trials using elecampane itself are absent.
Alantolactone, the principal sesquiterpene lactone of elecampane, has demonstrated antifungal activity against Candida albicans and other Candida species in published in vitro studies. Mechanisms include disruption of cell membrane integrity, inhibition of biofilm formation, and induction of reactive oxygen species. All evidence is preclinical.
Multiple in vitro and animal studies demonstrate that elecampane extracts and alantolactone suppress key inflammatory pathways including NF-κB, TNF-α, IL-1β, IL-6, iNOS, and neutrophil activation. These effects have been replicated across several independent research groups. All evidence is preclinical.
Alantolactone from elecampane has been studied in vitro and in animal models for dermatitis-related inflammatory skin conditions. A 2021 PMC-indexed study demonstrated it attenuates psoriasis-like skin lesions in a mouse model by suppressing keratinocyte hyperproliferation and inflammatory cytokines via STAT3 and NF-κB inhibition. A murine atopic dermatitis model using elecampane sesquiterpene lactones has also been published.
Elecampane's sesquiterpene lactones alantolactone and isoalantolactone have demonstrated antifungal activity in vitro against dermatophytes including Trichophyton and Microsporum species that cause skin infections, as well as against Candida species. Evidence is entirely in vitro.
Elecampane root contains up to 44% inulin, a prebiotic fructooligosaccharide with robust clinical evidence for selectively promoting beneficial gut bacteria including Bifidobacterium and Lactobacillus species. Clinical trials of inulin supplementation support microbiome modulation, though trials using elecampane root directly are absent.
Alantolactone from elecampane root has documented anthelmintic (anti-parasitic) activity, and a published study evaluated traditional herbs including elecampane against Ascaris lumbricoides. The British Herbal Pharmacopoeia and multiple ethnobotanical records confirm historical use against intestinal worms. In vitro and limited animal data are available.
Elecampane has a well-documented traditional role as a digestive herb for indigestion, bloating, wind, nausea, and abdominal discomfort across Western, Ayurvedic, and Chinese traditional medicine. It is classified as a stomachic and carminative in herbal pharmacopoeias. One 1977 clinical trial in peptic ulcer patients provides limited historical clinical context.
Elecampane root has a long history of use as a bitter digestive tonic, with the bitter constituents traditionally credited with stimulating appetite and digestive secretions. This use is documented across Western, Ayurvedic, and TCM traditions. No controlled clinical trials have evaluated this effect specifically.
Ayurvedic medicine uses elecampane (Inula helenium) for rheumatism and joint pain, and its anti-rheumatic properties are noted across traditional systems. In vitro anti-inflammatory evidence provides mechanistic plausibility. No clinical trials have examined elecampane for arthritis.
Asthma is one of the three principal proposed traditional uses of elecampane, listed alongside chronic respiratory diseases and poor digestion by EBSCO Research Starters. Its use for asthma is documented in ancient Greek, Ayurvedic, TCM, and Western herbalism. No controlled clinical trials exist.
Elecampane (Inula helenium) has been used in European and Asian herbal traditions for centuries to treat coughs associated with bronchitis, asthma, and whooping cough, classified as an expectorant and mild bronchospasmolytic. Its active constituent inulin and sesquiterpene lactones (including alantolactone) contribute to its mucus-clearing and antimicrobial properties. Evidence is primarily traditional, with limited clinical study data.
Elecampane (Inula helenium) has a centuries-long specific traditional use for bronchitis-associated cough in Western herbal and Eclectic medicine. It is listed as a proposed bronchitis treatment by the EBSCO evidence database. Its sesquiterpene lactone alantolactone is anti-inflammatory and the inulin content provides mucilaginous expectorant action.
Elecampane has been used in European, Ayurvedic, and Chinese traditional medicine for coughs and upper respiratory symptoms associated with colds. The British Herbal Pharmacopoeia lists it as an antitussive and antiseptic expectorant. No clinical trials for cold or flu specifically have been conducted.
Elecampane (Inula helenium) has a documented traditional use in COPD, chronic bronchitis, and emphysema. It contains alantolactone and inulin, which stimulate expulsion of thick sticky mucus—vital in COPD where mucus accumulation impairs breathing. Herbal Reality, an authoritative herbalism source, specifically identifies elecampane for COPD and chronic bronchitis.
Traditional Western and Ayurvedic herbalism describes elecampane as a bitter tonic that stimulates bile flow from the liver through the gallbladder into the small intestine, thereby aiding digestion of fats. This choleretic/cholagogue action is attributed to its bitter sesquiterpene lactones. No clinical trials support this specific use.
Elecampane (Inula helenium) has been used in European, Ayurvedic, and Chinese traditional medicine for respiratory conditions including asthma, bronchitis, whooping cough, tuberculosis, and pleurisy. Its active compounds inulin and alantolactone soothe bronchial passages and provide expectorant and antitussive action.
Elecampane (Inula helenium) root is a well-established traditional expectorant with mucolytic properties that thin and clear phlegm from the lungs. Used by Native Americans and in Western herbalism for lung diseases including bronchitis. Its sesquiterpene lactones possess antimicrobial and expectorant properties, and multiple herbal pharmacopeias describe it as an effective mucolytic expectorant.
Elecampane (Inula helenium) root has been used in traditional European herbal medicine specifically for whooping cough, documented in 19th- and early 20th-century herbal texts as an expectorant and respiratory tonic. The ADAM Complementary and Alternative Medicine pertussis resource explicitly lists elecampane, and the 2006 Abascal and Yarnell review included it among pertussis botanicals warranting study.
Elecampane (Inula helenium) has a long tradition of use in Western, Ayurvedic, and Traditional Chinese medicine for respiratory ailments including pleurisy. Herbalists have historically employed it as an expectorant, bronchospasmolytic, and antimicrobial to clear deep lung infections. It is listed among primary respiratory herbs in traditional pleurisy formulas alongside pleurisy root.
Elecampane has been used across multiple traditional systems as a respiratory tonic for coughs and mucus-related complaints, aligning with seasonal respiratory challenges. Its expectorant and antibacterial properties underpin this traditional role. No clinical trials have assessed seasonal respiratory use specifically.
Traditional Western and Eclectic herbalism used elecampane for pharyngitis and sore throat, often as a decoction or gargle, leveraging its antibacterial and anti-inflammatory properties. Western herbalists specifically list it for bronchitis and pharyngitis. No clinical trials have evaluated this use.
Upper respiratory support—particularly for bronchitis, whooping cough, and cough with excessive mucus—represents elecampane's primary and most consistently documented traditional indication, recorded in the British Herbal Pharmacopoeia, BHP, ancient Greek texts, Ayurveda, and TCM. Evidence is traditional with mechanistic in vitro support but no clinical trials.
Elecampane gained its traditional name 'scabwort' from topical use of the root boiled in vinegar as a salve for scabs, skin sores, and wounds. Irish and general European ethnomedical literature documents its use for dermal ailments. In vitro antimicrobial evidence provides mechanistic support. No clinical wound-healing trials exist.
Body systems that Elecampane may help support.
Go back